CSO Speaks at US National Research Meeting

Solvonis Therapeutics plc

(“Solvonis” or the “Company”)

Solvonis Chief Scientific Officer Professor David Nutt to Speak at U.S. National Institutes of Health Addiction Research Meeting

Professor Nutt to speak on psychedelic therapy for addictions at major U.S. federal addiction-research forum

Solvonis’ Chief Scientific Officer to participate alongside senior leaders from NIDA, NIAAA and NCI, the principal U.S. federal bodies shaping addiction research

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (“CNS”) disorders, notes that Professor David Nutt, Chief Scientific Officer of Solvonis, is scheduled to speak at a high-profile public addiction research meeting convened by the U.S. National Institutes of Health (“NIH”).

Professor Nutt is expected to speak on psychedelic therapy for addictions at the 14th Joint Meeting / 13th CRAN of the National Advisory Council on Alcohol Abuse and Alcoholism, the National Cancer Advisory Board and the National Advisory Council on Drug Abuse, taking place on 6 May 2026.

The NIH is the principal medical research agency of the United States government and the world’s largest single public funder of biomedical and behavioural research, with an annual budget of more than US$47 billion.

CRAN — Collaborative Research on Addiction at NIH — is the NIH partnership through which the National Institute on Alcohol Abuse and Alcoholism (“NIAAA”), the National Institute on Drug Abuse (“NIDA”) and the National Cancer Institute (“NCI”) coordinate research across substance use, misuse, addiction and related health consequences.

The meeting brings together senior U.S. federal leaders in addiction-related research, including Dr Nora Volkow, Director of NIDA, and Dr George Koob, Director of NIAAA. Professor Nutt is the sole external speaker, placing Solvonis’ Chief Scientific Officer in a prominent U.S. forum alongside senior figures who help shape the U.S. national scientific and funding priorities for alcohol, drug-use and addiction-related disorders.

Relevance to Solvonis

For UK investors, the relevance is clear. Solvonis is a London-listed CNS biopharmaceutical company focused on high-burden addiction and psychiatric disorders, operating in therapeutic areas attracting increasing scientific, policy and commercial attention in the United States and globally.

NIDA and NIAAA are among the most influential addiction-research institutions in the world. Published U.S. budget materials show the scale of these organisations, with NIDA’s FY2025 budget request at approximately US$1.67 billion and NIAAA’s FY2025 appropriation at approximately US$595 million.

Professor Nutt’s participation highlights the calibre, relevance and international profile of Solvonis’ scientific leadership. His expected presentation on psychedelic therapy for addictions is directly relevant to the field in which Solvonis is developing its addiction-focused pipeline: innovative CNS pharmacology combined, where appropriate, with structured psychosocial support.

Solvonis’ addiction-focused pipeline includes:

·       SVN-001, the Company’s late-stage ketamine-assisted therapy programme for severe Alcohol Use Disorder, currently being evaluated in a UK Phase 3 study;

·       SVN-002, the Company’s U.S.-focused esketamine oral thin film programme for moderate-to-severe Alcohol Use Disorder, which is being developed with structured psychosocial support; and

·       SVN-015, the Company’s preclinical programme for stimulant-use disorders, which has been selected for evaluation through the U.S. National Institute on Drug Abuse’s Addiction Treatment Discovery Program.

Together, these programmes position Solvonis across alcohol and substance-use disorders, with a pipeline spanning late-stage clinical development, U.S.-focused mid-clinical development and earlier-stage discovery in areas of significant unmet medical need.

CEO Comment

Anthony Tennyson, Chief Executive Officer of Solvonis, commented:

“This is a high-profile U.S. addiction-research forum convened through the NIH’s cross-institute CRAN initiative, bringing together NIDA, NIAAA and NCI — the principal U.S. federal bodies active in addiction-related research.

“Professor Nutt’s participation as the sole external academic speaker listed for the public session reflects his international standing in addiction neuroscience, neuropsychopharmacology and psychedelic-assisted therapy.

“For Solvonis, this is highly relevant. We are a UK-listed CNS biopharmaceutical company advancing programmes across Alcohol Use Disorder, addiction and psychiatry, including a NIDA-linked preclinical programme in stimulant-use disorders.

“This does not imply endorsement of Solvonis or its programmes by NIH, NIDA, NIAAA or NCI. It does, however, underline that the scientific themes central to our strategy are being discussed at the highest levels of the U.S. addiction-research community.”

Important Notice

Professor Nutt is listed by NIH in his academic capacity at Imperial College London. This announcement does not imply endorsement of Solvonis, its programmes, its product candidates or its development strategy by NIH, NIDA, NIAAA, NCI or any U.S. government agency.

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
info@solvonis.com

Singer Capital Markets (Broker)
Phil Davies
+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.

The Company’s lead programmes target Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company’s PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain signalling systems associated with emotional processing and social behaviour.

In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company’s integrated approach to developing therapies across addiction and psychiatry.

With a capital-efficient development model and a focus on partnering opportunities, Solvonis aims to deliver sustained value through innovation in CNS therapeutics.

solvonis.com | LinkedIn | X (Twitter)